BiotechTube
FutraMed

FutraMed

San Diego, United States· Est.
futramed.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

FutraMed is a clinical-stage medical device company focused on addressing the opioid crisis through its patented Limoge TCES (Transcutaneous Cranial Electrical Stimulation) device. The technology, based on decades of research by Dr. Aimé Limoge, is designed to potentiate the effects of opioids, allowing for dose reduction and alleviation of withdrawal symptoms, thereby targeting both chronic pain management and opioid use disorder. The company holds a CE Mark (2020) for commercialization in Europe and a U.S. patent but is not yet authorized for sale in the USA, and is actively seeking investment to advance commercialization efforts.

Chronic PainOpioid Use DisorderAddiction Medicine

Technology Platform

Transcutaneous Cranial Electrical Stimulation (TCES) using the proprietary Limoge Current, a specific waveform of balanced electrical pulses applied to the head to modulate the central nervous system, potentiate opioid effects, and alleviate withdrawal symptoms.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The massive and growing public health crisis of chronic pain and opioid addiction creates a urgent need for non-addictive, adjunctive therapies.
Securing a CE Mark provides a direct path to commercialize in the European Union and other recognizing countries, allowing for early revenue generation and clinical proof-of-concept.

Risk Factors

The company is pre-revenue and actively seeking investment, creating significant financial and execution risk.
Gaining FDA authorization for the U.S.
market is an uncertain, costly, and time-consuming regulatory hurdle.
Commercial adoption requires convincing clinicians to adopt a novel neuromodulation approach in a competitive treatment landscape.

Competitive Landscape

FutraMed competes in the broad neuromodulation space for pain (e.g., spinal cord stimulators, TENS units) and the addiction treatment market, which includes medications like buprenorphine and naloxone, behavioral therapies, and emerging digital health tools. Its direct competition includes other cranial stimulation devices, but its specific Limoge Current and historical data in opioid potentiation may differentiate it.

More companies in Neuroscience & CNS →More companies in United States →